CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- FinancialsLow earnings quality
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
872.53MUSDvs all stocks (USD)
Revenue (TTM)
204.89MUSDvs all stocks (USD)
Profit Margin
-76.77%vs Biotechnology peers
Beta
0.4870xvs all stocks
52-Week Change
39.72%vs all stocks
Market Capitalization
872.53MUSDvs all stocks (USD)
Enterprise Value
1.24BUSDvs all stocks (USD)
Forward P/E
7.60xvs Biotechnology peers
Price to Sales (TTM)
4.26xvs Biotechnology peers
Enterprise to Revenue
6.05xvs Biotechnology peers
Enterprise to EBITDA
-12.90xvs Biotechnology peers
Gross Margin
79.42%vs Biotechnology peers
Profit Margin
-76.77%vs Biotechnology peers
Operating Margin
-26.55%vs Biotechnology peers
Return on Assets (TTM)
-20.15%vs Biotechnology peers
Revenue (TTM)
204.89MUSDvs all stocks (USD)
Revenue per Share (TTM)
2.72USDUpdated Jul 19, 2026Quarterly Revenue Growth
104.40%vs Biotechnology peers
Gross Profit (TTM)
174.02MUSDvs all stocks (USD)
EBITDA (TTM)
-96.03MUSDvs all stocks (USD)
Net Income (TTM)
-157.30MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
104.43%vs Biotechnology peers
Operating Cash Flow (TTM)
-97.49MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-77.53MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
175.11MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
22.60MUSDFY2025 · Dec 31, 2025Gross Profit
152.51MUSDFY2025 · Dec 31, 2025Operating Income
-159.99MUSDvs all stocks (USD)
Pre-tax Income
-221.25MUSDFY2025 · Dec 31, 2025Net Income
-221.25MUSDFY2025 · Dec 31, 2025EBIT
-153.13MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-152.50MUSDFY2025 · Dec 31, 2025Research & Development
32.78MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
279.72MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
7.04MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
68.11MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-221.25MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-172.69MUSDFY2025 · Dec 31, 2025Free Cash Flow
-172.92MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
132.83MUSDFY2025 · Dec 31, 2025Interest Paid
21.37MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-221.25MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
633.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
28.72MUSDFY2025 · Dec 31, 2025Other Non-cash Items
37.22MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-39.33MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
34.10MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-12.78MUSDFY2025 · Dec 31, 2025Capital Expenditures
-229.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-229.00KUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Other Financing Charges
-1.93MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-1.93MUSDFY2025 · Dec 31, 2025Shares Outstanding
79.44MSharesUpdated Jul 19, 2026Float Shares
60.34MSharesUpdated Jul 19, 2026Shares Short
11.99MSharesUpdated Jul 19, 2026Short Ratio
11.19daysvs all stocks
Short % of Shares Outstanding
15.84%vs all stocks
% Held by Insiders
4.73%vs all stocks
% Held by Institutions
89.58%vs all stocks
Total Cash (MRQ)
180.90MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.27USDUpdated Jul 19, 2026Total Debt (MRQ)
547.22MUSDvs all stocks (USD)
Current Ratio (MRQ)
2.21xvs Biotechnology peers
Book Value per Share (MRQ)
-4.24USDUpdated Jul 19, 2026Total Assets
259.15MUSDvs all stocks (USD)
Total Current Assets
228.97MUSDFY2025 · Dec 31, 2025Total Liabilities
697.32MUSDFY2025 · Dec 31, 2025Total Non-current Assets
30.18MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
565.27MUSDFY2025 · Dec 31, 2025Total Current Liabilities
132.04MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
129.97MUSDFY2025 · Dec 31, 2025Accounts Receivable
78.13MUSDFY2025 · Dec 31, 2025Inventory
5.52MUSDFY2025 · Dec 31, 2025Accounts Payable
4.98MUSDFY2025 · Dec 31, 2025Short-term Debt
648.00KUSDFY2025 · Dec 31, 2025Other Current Liabilities
34.75MUSDFY2025 · Dec 31, 2025Long-term Debt
211.15MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
354.12MUSDFY2025 · Dec 31, 2025Common Stock (Book)
6.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.48BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
-438.17MUSDvs all stocks (USD)
Treasury Stock
0.00USDFY2025 · Dec 31, 202552-Week Low
7.61USDUpdated Jul 19, 202652-Week High
18.31USDUpdated Jul 19, 202652-Week Change
39.72%vs all stocks
Beta
0.4870xvs all stocks
50-Day MA
11.04USDUpdated Jul 19, 2026200-Day MA
12.70USDUpdated Jul 19, 2026Avg 10-Day Volume
1.28MSharesUpdated Jul 19, 2026Avg 30-Day Volume
1.05MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-2.09USDUpdated Jul 19, 2026Other Income / Expense
-190.00KUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
Where is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.79Profit Margin: -0.77
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.61
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Jinghua Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Amphastar Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Kaibao Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Oxford Biomedica plc
Tier 1ProductionApproval-Gated PipelineFlowRule
Sana Biotechnology, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Heilongjiang ZBD Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Theravance Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Warrants Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Boji Medical & Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hpgc Renmintongtai Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Alignment Healthcare, Inc.
2 interpretationsRevenue Growing With Receivables GrowingUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Doctorglasses Chain Co. Ltd.
2 interpretationsRevenue Growing With Receivables GrowingUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Innodata Inc.
2 interpretationsRevenue Growing With Receivables GrowingUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated